Search

Your search keyword '"Bar-Sela, Gil"' showing total 681 results
Start Over Author "Bar-Sela, Gil"
681 results on '"Bar-Sela, Gil"'

2. Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry

Author

Shachar, Shlomit S., Leviov, Michelle, Yerushalmi, Rinat, Drumea, Karen, Tokar, Margarita, Soussan-Gutman, Lior, Bareket-Samish, Avital, Sonnenblick, Amir, Ben-Baruch, Noa, Evron, Ella, Gal-Yam, Einav Nili, Paluch-Shimon, Shani, Bar-Sela, Gil, Goldvaser, Hadar, and Stemmer, Salomon M.

Published
2023
Full Text
View/download PDF

6. Evaluation of immune response to anti‐COVID‐19 booster in cancer patients and chronic medical cannabis users and its association with circulating Eosinophils levels

Author

Cohen Idan, Campisi‐Pinto Salvatore, Rozenberg Orit, Abaev Ariel, Khoury Marah, Agbaria Dana, Eitam Harel, Colodner Raul, Khoury Mona, Shalabna Hassan, Samih Yousef, Mahamid Camel, Abu‐Amna Mahmoud, and Bar‐Sela Gil

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2022
Full Text
View/download PDF

8. Neutrophil degranulation and severely impaired extracellular trap formation at the basis of susceptibility to infections of hemodialysis patients

Author

Salti Talal, Khoury Mona, Awad Karem, Lerenthal Yaniv, Harari-Misgav Reut, Shemesh Ariel, Avraham-Kelbert Moran, Eitam Harel, Salvatore Campisi-Pinto, Abu-Amna Mahmoud, Colodner Raul, Tovbin David, Bar-Sela Gil, and Cohen Idan

Subjects
Neutrophils, Hemodialysis, Infections, Neutrophil degranulation, Neutrophil extracellular traps (NETosis), Medicine
Abstract

Abstract Background Chronic kidney disease patients are at increased risk of mortality with cardiovascular diseases and infections as the two leading causes of death for end-stage kidney disease treated with hemodialysis (HD). Mortality from bacterial infections in HD patients is estimated to be 100–1000 times higher than in the healthy population. Methods We comprehensively characterized highly pure circulating neutrophils from HD and healthy donors. Results Protein levels and transcriptome of HD patients’ neutrophils indicated massive neutrophil degranulation with a dramatic reduction in reactive oxygen species (ROS) production during an oxidative burst and defective oxidative cellular signaling. Moreover, HD neutrophils exhibit severely impaired ability to generate extracellular NET formation (NETosis) in NADPH oxidase-dependent or independent pathways, reflecting their loss of capacity to kill extracellular bacteria. Ectopic hydrogen peroxidase (H2O2) or recombinant human SOD-1 (rSOD-1) partly restores and improves the extent of HD dysfunctional neutrophil NET formation. Conclusions Our report is one of the first singular examples of severe and chronic impairment of NET formation leading to substantial clinical susceptibility to bacteremia that most likely results from the metabolic and environmental milieu typical to HD patients and not by common human genetic deficiencies. In this manner, aberrant gene expression and differential exocytosis of distinct granule populations could reflect the chronic defect in neutrophil functionality and their diminished ability to induce NETosis. Therefore, our findings suggest that targeting NETosis in HD patients may reduce infections, minimize their severity, and decrease the mortality rate from infections in this patient population.

Published
2022
Full Text
View/download PDF

9. Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5-/- mice.

Author

Li, Yan, Tinoco, Roberto, Elmén, Lisa, Segota, Igor, Xian, Yibo, Fujita, Yu, Sahu, Avinash, Zarecki, Raphy, Marie, Kerrie, Feng, Yongmei, Khateb, Ali, Frederick, Dennie T, Ashkenazi, Shiri K, Kim, Hyungsoo, Perez, Eva Guijarro, Day, Chi-Ping, Segura Muñoz, Rafael S, Schmaltz, Robert, Yooseph, Shibu, Tam, Miguel A, Zhang, Tongwu, Avitan-Hersh, Emily, Tzur, Lihi, Roizman, Shoshana, Boyango, Ilanit, Bar-Sela, Gil, Orian, Amir, Kaufman, Randal J, Bosenberg, Marcus, Goding, Colin R, Baaten, Bas, Levesque, Mitchell P, Dummer, Reinhard, Brown, Kevin, Merlino, Glenn, Ruppin, Eytan, Flaherty, Keith, Ramer-Tait, Amanda, Long, Tao, Peterson, Scott N, Bradley, Linda M, and Ronai, Ze'ev A

Subjects
Intestines, Animals, Mice, Inbred C57BL, Mice, Knockout, Humans, Mice, Bacteria, Melanoma, Ubiquitin-Protein Ligases, Antimicrobial Cationic Peptides, Membrane Proteins, Cell Proliferation, Unfolded Protein Response, Gastrointestinal Microbiome, Inbred C57BL, Knockout
Abstract

Accumulating evidence points to an important role for the gut microbiome in anti-tumor immunity. Here, we show that altered intestinal microbiota contributes to anti-tumor immunity, limiting tumor expansion. Mice lacking the ubiquitin ligase RNF5 exhibit attenuated activation of the unfolded protein response (UPR) components, which coincides with increased expression of inflammasome components, recruitment and activation of dendritic cells and reduced expression of antimicrobial peptides in intestinal epithelial cells. Reduced UPR expression is also seen in murine and human melanoma tumor specimens that responded to immune checkpoint therapy. Co-housing of Rnf5-/- and WT mice abolishes the anti-tumor immunity and tumor inhibition phenotype, whereas transfer of 11 bacterial strains, including B. rodentium, enriched in Rnf5-/- mice, establishes anti-tumor immunity and restricts melanoma growth in germ-free WT mice. Altered UPR signaling, exemplified in Rnf5-/- mice, coincides with altered gut microbiota composition and anti-tumor immunity to control melanoma growth.

Published
2019

13. Case report: Conjunctival melanoma treated with relatlimab and nivolumab showing remarkable response.

Author

Attrash, Mirona, Badran, Omar, Shapira, Yinon, and Bar-Sela, Gil

Subjects
DRUG efficacy, PROGRESSION-free survival, NIVOLUMAB, IMMUNOTHERAPY, DEMENTIA
Abstract

Conjunctival melanoma, an uncommon form of ocular melanoma, shares some molecular characteristics with cutaneous melanoma and some with mucosal melanoma. Treatment of cases where it becomes advanced or metastatic raises unique treatment challenges. Nivolumab/relatlimab (Opdualag) recently received FDA approval for metastatic melanoma based on the phase 2/3 RELATIVITY-047 trial, which showed better median progression-free survival (PFS) in the first-line setting without new safety signals. The efficacy of this drug in conjunctival melanoma has not been reported yet. Case presentation: An 87-year-old woman with a history of mild dementia was admitted to the oncology department with a large, exophytic tumor protruding from her left eye, diagnosed as conjunctival melanoma two years previously. This tumor was secreting a whitish fluid and obstructing her vision. Immunotherapy with Opdualag was started, with a near clinical complete response after the 1st cycle. The patient was treated with only four cycles due to worsening of her dementia. Conclusion: Nivolumab/relatlimab (Opdualag) is a promising treatment alternative in conjunctival melanoma when surgery is not viable. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline

Author

Braun, Ilana M., primary, Bohlke, Kari, additional, Abrams, Donald I., additional, Anderson, Holly, additional, Balneaves, Lynda G., additional, Bar-Sela, Gil, additional, Bowles, Daniel W., additional, Chai, Peter R., additional, Damani, Anuja, additional, Gupta, Arjun, additional, Hallmeyer, Sigrun, additional, Subbiah, Ishwaria M., additional, Twelves, Chris, additional, Wallace, Mark S., additional, and Roeland, Eric J., additional

Published
2024
Full Text
View/download PDF

18. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Author

Lesimple, Thierry, Maio, Michele, Linette, Gerald, Mortier, Laurent, Svane, Inge Marie, Schachter, Jacob, Brown, Michael, Hersey, Peter, Barrow, Catherine, Kudchadkar, Ragini, Dutriaux, Caroline, Song, Xinni, Quaglino, Pietro, Queirolo, Paola, Meier, Friedegund, Stroyakovskiy, Daniil, Guillot, Bernard, Romero, Pablo Luis Ortiz, Bastholt, Lars, Garbe, Claus, Grange, Florent, Mohr, Peter, Algazi, Alain, Bechter, Oliver, Hernberg, Micaela, Loquai, Carmen, Meiss, Frank, Chiarion Sileni, Vanna, Bar-Sela, Gil, Fitzharris, Bernard, Saiag, Philippe, Arnault, Jean-Philippe, Simon, Jan-Christoph, Stephens, Rosalie, Baurain, Jean-Francois, Lebbe, Célèste, Combemale, Patrick, Dummer, Reinhard, Hauschild, Axel, Parente, Phillip, Yamazaki, Naoya, Milhem, Mohammed, Leccia, Marie-Thérèse, Geoffrois, Lionel, Kretschmer, Lutz, Dunwoodie, Elaine, Walker, John, Lotem, Michal, Hendler, Daniel, Mackiewicz, Andrzej, Sekulovic, Lidija, Dzienis, Marcin, Hospers, Geke A.P., Siano, Marco, Hassel, Jessica, Corrie, Philippa, Passos, Maria-Jose, Levin, Max, Hoeller, Christoph, Machet, Laurent, Hallmeyer, Sigrun, Waterston, Ashita, Descamps, Vincent, Kiecker, Felix, Aarts, Maureen, Schmidt, Henrik, Raimundo, Ana, Nyakas, Marta, Lacour, Jean-Philippe, Berking, Carola, Ferrucci, Pier Francesco, Jameson, Michael, Kim, Kevin, Yokota, Kenji, Kerger, Joseph, Aubin, François, Groenewegen, Gerard, Kapiteijn, Helena, Boehncke, Wolf-Henning, Utikal, Jochen, Casasola, Richard, Marshall, Ernest, Ferraresi, Virginia, Richtig, Erika, Matkovic, Suzana, Inozume, Takashi, Crook, Timothy, McNeil, Catriona, Kiyohara, Yoshio, Avril, Marie-Francoise, Hein, Rüdiger, Terheyden, Patrick, Nathan, Paul, Aoi, Jun, Skytta, Tanja, Jouary, Thomas, Takenouchi, Tatsuya, Straume, Oddbjorn, Martins, César, Mukhametshina, Guzel, Bottomley, Andrew, Coens, Corneel, Mierzynska, Justyna, Blank, Christian U, Mandalà, Mario, Long, Georgina V, Atkinson, Victoria G, Dalle, Stéphane, Haydon, Andrew M, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Puig, Susana, Ascierto, Paolo A, Larkin, James, Lorigan, Paul C, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J M, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C J, Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, Robert, Caroline, and Eggermont, Alexander M M

Published
2021
Full Text
View/download PDF

19. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Author

Menzies, Alex, Lesimple, Thierry, Maio, Michele, Linette, Gerald, Brown, Michael, Hersey, Peter, Svane, Inge Marie, Mortier, Laurent, Schachter, Jacob, Barrow, Catherine, Kudchadkar, Ragini, Song, Xinni, Dutriaux, Caroline, Quaglino, Pietro, Meier, Friedegund, Queirolo, Paola, Stroyakovskiy, Daniil, Bastholt, Lars, Guillot, Bernard, Garbe, Claus, Ortiz Romero, Pablo Luis, Grange, Florent, Mohr, Peter, Algazi, Alain, Bechter, Oliver, Hernberg, Micaela, Arnault, Jean-Philippe, Saiag, Philippe, Loquai, Carmen, Meiss, Frank, Simon, Jan-Christoph, Bar-Sela, Gil, Chiarion Sileni, Vanna, Fitzharris, Bernard, McCrystal, Mike, Parente, Phillip, Baurain, Jean-Francois, Combemale, Patrick, Lebbe, Célèste, Hauschild, Axel, Yamazaki, Naoya, Dummer, Reinhard, Milhem, Mohammed, Dzienis, Marcin, Walker, John, Geoffrois, Lionel, Leccia, Marie-Thérèse, Kretschmer, Lutz, Hendler, Daniel, Lotem, Michal, Mackiewicz, Andrzej, Sekulovic, Lidija, Dunwoodie, Elaine, Hoeller, Christoph, Machet, Laurent, Hassel, Jessica, Hospers, Geke A.P., Passos, Maria-Jose, Levin, Max, Fehr, Martin, Corrie, Philippa, Waterston, Ashita, Hallmeyer, Sigrun, Schmidt, Henrik, Descamps, Vincent, Lacour, Jean-Philippe, Berking, Carola, Kiecker, Felix, Ferrucci, Pier Francesco, Yokota, Kenji, Aarts, Maureen, Jameson, Michael, Winge-Main, Anna Katharina, Ferreira, Paula, Kim, Kevin, McNeil, Catriona, Hofmann-Wellenhof, Reiner, Kerger, Joseph, Aubin, François, Utikal, Jochen, Ferraresi, Virginia, Inozume, Takashi, Kiyohara, Yoshio, Groenewegen, Gerard, Kapiteijn, Helena, Matkovic, Suzana, Boehncke, Wolf-Henning, Casasola, Richard, Crook, Timothy, Marshall, Ernest, Skytta, Tanja, Avril, Marie-Francoise, Jouary, Thomas, Hein, Rüdiger, Terheyden, Patrick, Aoi, Jun, Takenouchi, Tatsuya, Straume, Oddbjorn, Martins, César, Mukhametshina, Guzel, Nathan, Paul, Eggermont, Alexander M M, Blank, Christian U, Mandalà, Mario, Long, Georgina V, Atkinson, Victoria G, Dalle, Stéphane, Haydon, Andrew M, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J M, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul C, van Akkooi, Alexander C J, Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, and Robert, Caroline

Published
2021
Full Text
View/download PDF

25. Some differences between social work, spiritual care, and psychology: Content variance in end-of-life conversations.

Author

Schultz, Michael, Baziliansky, Svetlana, Mitnik, Inbal, Ulitzur, Nirit, Campisi-Pinto, Salvatore, Givoli, Simon, Bar-Sela, Gil, and Zalman, Daniela

Subjects
SOCIAL services, SPIRITUAL care (Medical care), PSYCHOLOGY, CAREGIVERS, CANCER patients
Abstract

Objectives: Within the multidisciplinary team, there can sometimes be lack of clarity as to the specific different contributions of each of the psycho-social-spiritual professionals: social workers, psychologist, and spiritual caregivers. This study examined the content of their end-of-life conversations with patients. Methods: A total of 180 patients with terminal cancer received standard multidisciplinary care, including conversations with a social worker, psychologist, and spiritual caregiver. After each patient's death, these professionals reported using a structured tool which content areas had arisen in their conversations with that patient. Results: Across all content areas, there were significant differences between social work and spiritual care. The difference between social work and psychology was slightly smaller but still quite large. Psychology and spiritual care were the most similar, though they still significantly differed in half the content areas. The differences persisted even among patients who spoke with more than 1 kind of professional. The 6 content areas examined proved to subdivide into 2 linked groups, where patients speaking about 1 were more likely to speak about the others. One group, "reflective" topics (inner and transpersonal resources, interpersonal relationships, one's past, and end of life), included all those topics which arose more often with spiritual caregivers or psychologists. The second group, "decision-making" topics (medical coping and life changes), was comprised of those topics which arose most commonly with social workers, bridging between the medical and personal aspects of care and helping patients navigate their new physical, psychological, and social worlds. Significance of results: These findings help shed light on the differences, in practice, between patients' conversations with social workers, psychologists, and spiritual caregivers and the roles these professionals are playing; can aid in formulating individualized care plans; and strengthen the working assumption that all 3 professions contribute in unique, complementary ways to improving patients' and families' well-being. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Linkage between Psychological Factors and Response to Immune Checkpoint Inhibitor Therapy: A Preliminary Study

Author

Cohen, Miri, primary, Shamay, Yosi, additional, Czamanski-Cohen, Johanna, additional, Shulman, Katerina, additional, Keren Rosenberg, Shoshana, additional, Abu-Amna, Mahmoud, additional, Turgeman, Ilit, additional, Merkin Livshits, Ludmila, additional, Birenboim, Revital, additional, Dines, Monica, additional, and Bar-Sela, Gil, additional

Published
2023
Full Text
View/download PDF

31. Challenges in implementing guideline on integrative oncology and pain: The Israeli perspective

Author

Ben-Arye, Eran, primary, Mao, Jun, additional, Bruera, Eduardo, additional, Samuels, Noah, additional, Keshet, Yael, additional, Lee, Richard T, additional, Ben-Yehuda, Dina, additional, Eisenberg, Elon, additional, Bar-Sela, Gil, additional, Shvartzman, Pesach, additional, Balneaves, Lynda G., additional, Shani, Michal, additional, Ellis, Martin, additional, Tripathy, Debu, additional, Ash, Shifra, additional, Elis, Avishay, additional, Vaknin, Zvi, additional, Ofir, Ruth, additional, and Schiff, Elad, additional

Published
2023
Full Text
View/download PDF

32. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

Author

Carlino, Matteo S., Long, Georgina V., Schadendorf, Dirk, Robert, Caroline, Ribas, Antoni, Richtig, Erika, Nyakas, Marta, Caglevic, Christian, Tarhini, Ahmed, Blank, Christian, Hoeller, Christoph, Bar-Sela, Gil, Barrow, Catherine, Wolter, Pascal, Zhou, Honghong, Emancipator, Kenneth, Jensen, Erin H., Ebbinghaus, Scot, Ibrahim, Nageatte, and Daud, Adil

Published
2018
Full Text
View/download PDF

35. Human Development Index and its association with staff spiritual care provision: a Middle Eastern oncology study

Author

Bar-Sela, Gil, Schultz, Michael J., Elshamy, Karima, Rassouli, Maryam, Ben-Arye, Eran, Doumit, Myrna, Gafer, Nahla, Albashayreh, Alaa, Ghrayeb, Ibtisam, Turker, Ibrahim, Ozalp, Gulcin, Kav, Sultan, Fahmi, Rasha, Nestoros, Sophia, Ghali, Hasanein, Mula-Hussain, Layth, Shazar, Ilana, Obeidat, Rana, Punjwani, Rehana, Khleif, Mohamad, Can, Gulbeyaz, Tuncel, Gonca, Charalambous, Haris, Faraj, Safa, Keoppi, Neophyta, Al-Jadiry, Mazin, Postovsky, Sergey, Al-Omari, Ma’an, Razzaq, Samaher, Ayyash, Hani, Khader, Khaled, Kebudi, Rejin, Omran, Suha, Rasheed, Osaid, Qadire, Mohammed, Ozet, Ahmet, and Silbermann, Michael

Published
2019
Full Text
View/download PDF

36. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Author

Ascierto, Paolo Antonio, Ferrucci, Pier Francesco, Fisher, Rosalie, Del Vecchio, Michele, Atkinson, Victoria, Schmidt, Henrik, Schachter, Jacob, Queirolo, Paola, Long, Georgina V., Di Giacomo, Anna Maria, Svane, Inge Marie, Lotem, Michal, Bar-Sela, Gil, Couture, Felix, Mookerjee, Bijoyesh, Ghori, Razi, Ibrahim, Nageatte, Moreno, Blanca Homet, and Ribas, Antoni

Published
2019
Full Text
View/download PDF

41. Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma

Author

Dummer, Reinhard, primary, Robert, Caroline, additional, Scolyer, Richard A., additional, Taube, Janis M., additional, Tetzlaff, Michael T., additional, Hill, Andrew, additional, Grob, Jean-Jacques, additional, Portnoy, David C., additional, Lebbe, Celeste, additional, Khattak, Muhammad A., additional, Cohen, Jonathan, additional, Bar-Sela, Gil, additional, Mehmi, Inderjit, additional, Frommer, Ronnie Shapira, additional, Meyer, Nicolas, additional, Ren, Yixin, additional, Fukunaga-Kalabis, Mizuho, additional, Krepler, Clemens, additional, and Long, Georgina V., additional

Published
2023
Full Text
View/download PDF

43. Data from DNA Methyltransferase 1 and 3B Activate BAG-1 Expression via Recruitment of CTCFL/BORIS and Modulation of Promoter Histone Methylation

Author

Sun, Lunching, primary, Huang, Lei, primary, Nguyen, Phuongmai, primary, Bisht, Kheem S., primary, Bar-Sela, Gil, primary, Ho, Allen S., primary, Bradbury, C. Matthew, primary, Yu, Wenqiang, primary, Cui, Hengmi, primary, Lee, Sunmin, primary, Trepel, Jane B., primary, Feinberg, Andrew P., primary, and Gius, David, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figures 1-4, Methods and Materials from DNA Methyltransferase 1 and 3B Activate BAG-1 Expression via Recruitment of CTCFL/BORIS and Modulation of Promoter Histone Methylation

Author

Sun, Lunching, primary, Huang, Lei, primary, Nguyen, Phuongmai, primary, Bisht, Kheem S., primary, Bar-Sela, Gil, primary, Ho, Allen S., primary, Bradbury, C. Matthew, primary, Yu, Wenqiang, primary, Cui, Hengmi, primary, Lee, Sunmin, primary, Trepel, Jane B., primary, Feinberg, Andrew P., primary, and Gius, David, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results